Previous close | 16.87 |
Open | 16.87 |
Bid | 17.15 |
Ask | 19.80 |
Strike | 60.00 |
Expiry date | 2024-01-19 |
Day's range | 16.87 - 16.87 |
Contract range | N/A |
Volume | |
Open interest | 1.14k |
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.